Kerry Ward, PharmD, BCPS, BCCCP, BCEMP (@kerryward10) 's Twitter Profile
Kerry Ward, PharmD, BCPS, BCCCP, BCEMP

@kerryward10

Clinical Pharmacy Specialist-Emergency Medicine. BCPS. BCCCP. BCEMP. It takes what it takes. #GoDawgs

ID: 426079270

calendar_today01-12-2011 20:26:30

13,13K Tweet

567 Followers

1,1K Following

Kerry Ward, PharmD, BCPS, BCCCP, BCEMP (@kerryward10) 's Twitter Profile Photo

For those that made the switch from alteplase to tenecteplase for AIS, what was the biggest problem that you noticed that you didn’t anticipate? Doing a presentation on this soon and wanted to poll the masses.

William Baker (@wbaker0621) 's Twitter Profile Photo

Pleasure presenting our working comparing high- vs low-dose 4F-PCC for treating factor Xa-associated ICH. There was no evidence of a difference between 4F-PCC doses for heloststic effectiveness & no VTE events. UConn Pharmacy #ESCCongress #ESC2023

Pleasure presenting our working comparing high- vs low-dose 4F-PCC for treating factor Xa-associated ICH. There was no evidence of a difference between 4F-PCC doses for heloststic effectiveness &amp; no VTE events. <a href="/UConnPharmacy/">UConn Pharmacy</a> #ESCCongress #ESC2023
Andy Webb (@ajwpharm) 's Twitter Profile Photo

A key point in ACLS is that in shockable rhythms, the ⚡ is key to improving outcomes A knee-jerk reaction in a code is to give epi, but epi before shock in a shockable rhythm WORSENS outcomes ⚡once, then ⚡ again, THEN give epi bmj.com/content/375/bm… bmj.com/content/353/bm…

A key point in ACLS is that in shockable rhythms, the ⚡ is key to improving outcomes

A knee-jerk reaction in a code is to give epi, but epi before shock in a shockable rhythm WORSENS outcomes

⚡once, then ⚡ again, THEN give epi

bmj.com/content/375/bm…
bmj.com/content/353/bm…
cardio-met (@cardiomet_ce) 's Twitter Profile Photo

1) Welcome to a 🆕#LIVE #accredited #tweetorial posted from #Toronto and #WSC2023, where we have just seen top-line results of #ANNEXa_I, the FIRST randomized comparison between #andexanet_alfa & usual care in pts with anti-#FXa #DOAC-associated #ICH.

Tara Lech PharmD, CACP (@anticoagpharmd) 's Twitter Profile Photo

Definitely was hoping for more of a wow factor after all the hype. 🤔 NO Difference in mortality or 30d outcomes ⬆️ TE events -> no surprise AA significantly ⬇️ anti-FXa vs PCC Would have loved to see a simultaneous publication… still waiting on the details 👀 #ANNEXAi #WSC2023

Mike Erdman (@erdapenum1) 's Twitter Profile Photo

So if you had an anticoagulant reversal medication that stopped hematoma expansion, but had no effect on 30-day outcomes, and had a 4x increased risk of ischemic stroke, would you give it? #ANNEXa_I

Scott Dietrich (@pcc_pharmd) 's Twitter Profile Photo

Some of the Anexxa-I results are out. Looks like excellent/good hemostasis was 64% vs 52% with Anexxa vs "usual care" but no difference in 30-day mortality or functional outcomes and higher VTE risk of 10% vs 6%. Still want the full text....

Casey Albin, MD (@caseyalbin) 's Twitter Profile Photo

🥵 In ICH 1 mL hematoma expansion = 5% 🔼 in the odds of death or dependence! A call to action to improve the care of pts with ICH by: 1⃣ Bundled care 2⃣ time-based metrics An excellent review of the literature in ICH and what we can do moving forward: ahajournals.org/doi/10.1161/ST…

🥵 In ICH 1 mL hematoma expansion = 5% 🔼 in the odds of death or dependence!

A call to action to improve the care of pts with ICH by:
1⃣ Bundled care
2⃣ time-based metrics

An excellent review of the literature in ICH and what we can do moving forward:
ahajournals.org/doi/10.1161/ST…